Rocha A, Malheiro J, Martins L S, Fonseca I, Dias L, Pedroso S, Almeida M, Henriques A C
Department of Nephrology, Centro Hospitalar do Porto, Porto, Portugal.
Transplant Proc. 2013 Jul-Aug;45(6):2141-6. doi: 10.1016/j.transproceed.2012.11.013. Epub 2013 Jun 6.
Diabetes mellitus (DM) is the most prevalent cause of kidney failure. Some concerns have been raised about the kidney transplantation (KT) results in diabetic patients. Therefore, we compared outcomes between diabetic and non-diabetic KT patients.
We included all KT performed in type 2 diabetic patients in our center from July 1983 to December 2009 with graft survivals beyond 3 months. Nondiabetic controls were individually matched with diabetic patients with respect to gender, age, year of transplantation, number of donor HLA mismatches, and dialysis vintage. The two groups were compared concerning patient and graft survivals, delayed graft function (DGF), and prevalence of acute rejection episodes (ARE).
The 62 diabetic and 62 nondiabetic patients had a mean follow-up after KT of 102 ± 64 months. Diabetic patients and controls were similar for the matched variables. Death censored graft survivals of diabetics versus nondiabetics were 70% and 83% at 5 years and 54% and 71% at 10 years, respectively (P = .13). Patient survivals at 5 and 10 years were 69% and 50% for diabetic versus 96% and 84% for nondiabetic patients, respectively (P < .001). The prevalence of ARE and DGF did not differ (chi-squared test, P = .12). Multivariate Cox's proportional hazards analysis revealed DM (hazard ratio [HR] 7.72; P = .001) and viral hepatitis (HR = 4.18; P = .02) to correlate with reduced patient survival.
Survival of diabetic patients after KT was reduced but death-censored graft outcomes were similar compared with matched nondiabetic patients. Concerns about graft survival should not prevent KT for diabetic patients with kidney failure.
糖尿病(DM)是肾衰竭最常见的病因。人们对糖尿病患者的肾移植(KT)结果提出了一些担忧。因此,我们比较了糖尿病和非糖尿病KT患者的结局。
我们纳入了1983年7月至2009年12月在本中心为2型糖尿病患者进行的所有KT,且移植肾存活超过3个月。非糖尿病对照组在性别、年龄、移植年份、供体HLA错配数和透析时间方面与糖尿病患者进行个体匹配。比较两组患者和移植肾的存活率、移植肾功能延迟恢复(DGF)以及急性排斥反应(ARE)的发生率。
62例糖尿病患者和62例非糖尿病患者在KT后的平均随访时间为102±64个月。糖尿病患者和对照组在匹配变量方面相似。糖尿病患者与非糖尿病患者的死亡校正移植肾存活率在5年时分别为70%和83%,在10年时分别为54%和71%(P = 0.13)。糖尿病患者在5年和10年时的患者存活率分别为69%和50%,而非糖尿病患者分别为96%和84%(P < 0.001)。ARE和DGF的发生率没有差异(卡方检验,P = 0.12)。多变量Cox比例风险分析显示,糖尿病(风险比[HR] 7.72;P = 0.001)和病毒性肝炎(HR = 4.18;P = 0.02)与患者生存率降低相关。
与匹配的非糖尿病患者相比,糖尿病患者KT后的生存率降低,但死亡校正后的移植肾结局相似。对移植肾存活的担忧不应妨碍为肾衰竭的糖尿病患者进行KT。